Tim Keane
CEO

TYBR is developing a sprayable hydrogel designed to prevent internal organ scarring after surgical procedures, enhancing the body's natural healing process without synthetic materials. This technology aims to reduce the incidence of function-limiting adhesions, thereby minimizing recovery time and complications for patients.
Funding not disclosed



Following surgical procedures, internal organ scarring and tissue tethering can impede the body's natural healing process, leading to function-limiting adhesions. These complications can result in extended recovery times, the need for secondary procedures, and reduced patient mobility.
TYBR Health is developing B3 GEL™, a flowable bio-gel barrier designed to prevent post-surgical tissue tethering and promote optimal healing. This proprietary extracellular matrix (ECM) hydrogel acts as a protective shield for tendons and ligaments during the critical initial healing phase. B3 GEL™ selectively allows essential nutrients and growth factors to reach tissues while blocking excessive scarring. The hydrogel remains in place for the first week post-surgery, protecting tissues through acute inflammation and fibroblast proliferation, and then naturally metabolizes over the following 2-3 weeks, leaving no residual material behind.
The primary target audience includes surgeons specializing in hand, wrist, foot, and ankle procedures, as well as hospitals and surgical centers focused on improving post-operative outcomes and reducing recovery times.